Multiple Myeloma Coverage from Every Angle
ABOUT
SECTIONS
JNCCN Spotlights
Videos
News
Medical Literature
CE Activities
Clinical Trials
For Your Patients
NCCN RESOURCES
NCCN Guidelines
®
NCCN Compendium
®
NCCN Templates
®
NCCN Guidelines for Patients®
360 HUB
Advanced Skin Cancers
CLL/MCL
Multiple Myeloma
Non–Small Cell Lung Cancer
Ovarian Cancer
JNCCN
Editor:
Shaji K. Kumar, MD
Advertisement
Advertisement
News
FDA Grants Accelerated Approval to Iberdomide With Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
Alpha-Emitting Radioimmunotherapy Shows Activity in Daratumumab-Refractory Myeloma
ASCO 2026: Etentamig Demonstrates Activity After Prior BCMA-Targeted Therapy in Relapsed/Refractory Multiple Myeloma
FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
ASCO 2026: Mezigdomide Triplet Improves Progression-Free Survival in Relapsed or Refractory Multiple Myeloma
ASCO 2026: Elranatamab Shows Promising Early Activity in High-Risk Smoldering Multiple Myeloma
AACR 2026: Cilta-cel Shows Rapid, Durable Responses in High-Risk Smoldering Myeloma
JNCCN Spotlights
?
(UPDATE) Ixazomib
Update Carfilzomib Kyprolis
Elotuzumab
View More >
Advertisement
Resources
For your Patients
Copyright ©
2026
National Comprehensive Cancer Network, All Rights Reserved
Bots not welcome here
